ArticleThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology2026
LncRNA KCNQ1OT1 aggravates myocardial ischemia/reperfusion injury by mediating the EZH2/TIMP-3 axis.
Article in The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study focused on discussing the mechanism of lncRNA KCNQ1OT1 mediating histone methylase enhancer of zeste homolog 2 (EZH2) to repress tissue inhibitor of metalloproteinase-3 (TIMP-3) expression in myocardial ischemia/reperfusion injury (MI/RI). Ischemia-hypoxia hypoxia/reoxygenation (H/R) models were successfully constructed by utilizing primary cardiomyocytes. KCNQ1OT1 and TIMP-3 expression in cardiomyocytes was tested. The proliferative capacity of the cells was assessed. The changes of lactate dehydrogenase (LDH), superoxide dismutase (SOD), and malondialdehyde (MDA) contents in the supernatant of primary cardiomyocytes and Caspase-3 activity were measured. The apoptosis of primary cardiomyocytes was tested. The interactions of KCNQ1OT1, EZH2 and TIMP-3 were verified. Compared to the control group, KCNQ1OT1 expression levels, supernatant LDH and MDA levels, Caspase-3 activity, and cardiomyocyte apoptosis rate in the H/R group were elevated, and cell viability, TIMP-3 expression, and supernatant SOD levels were decreased. After KCNQ1OT1 interference or TIMP-3 overexpression, LDH and MDA levels, Caspase-3 activity, and cardiomyocyte apoptosis rate were reduced, while cell viability, TIMP-3 expression, and SOD levels were raised. Interfering TIMP-3 reversed the ameliorative effects of KCNQ1OT1 downregulation on MI/RI. Mechanistically, KCNQ1OT1 inhibited TIMP-3 expression by recruiting EZH2 to the TIMP-3 promoter region. Interference with KCNQ1OT1 could block EZH2 to the TIMP-3 promoter region and thereby up-regulate TIMP-3 expression, which possesses an ameliorative impact on MI/RI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.